71 – 80 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
- Contribution to journal › Article
-
Mark
Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer’s disease.
(2010) 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
- Contribution to conference › Poster
- 2009
-
Mark
Medial Temporal Lobe Atrophy Increases the Specificity of Cerebrospinal Fluid Biomarkers in Alzheimer Disease with Minor Cerebrovascular Changes.
- Contribution to journal › Article
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Cholinesterase Inhibitor Treated Naturalistic Alzheimer Patients.
(2009) 9th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
- Contribution to conference › Poster
- 2008
-
Mark
Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting.
- Contribution to journal › Article
-
Mark
Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease.
- Contribution to journal › Article
- 2007
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
- Contribution to journal › Article
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of Daily Living – Outcome During Three Years in Donepezil Treated Alzheimer Patients.
(2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress
- Contribution to conference › Poster
